Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations

Vaccine

Volumn 30, Issue 24, 2012, Pages 3580-3586

  Parra, Gabriel I ^a   Bok, Karin ^a   Taylor, Ross ^b   Haynes, Joel R ^b   Sosnovtsev, Stanislav V ^a   Richardson, Charles ^b   Green, Kim Y ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b LigoCyte Pharmaceuticals Inc   (United States)

Author keywords

Consensus virus like particles; Gastroenteritis; GII.4 noroviruses; Noroviruses

Indexed keywords

ALUMINUM HYDROXIDE; EPITOPE; NOROVIRUS CONSENSUS GII.4 VIRUS LIKE PARTICLE VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CROSS REACTION; DRUG FORMULATION; GENOTYPE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; NOROVIRUS; NOROVIRUS INFECTION; PRIORITY JOURNAL; VIRUS LIKE AGENT; WILD TYPE;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANIMALS; ANTIBODIES, VIRAL; CROSS REACTIONS; FEMALE; GENOTYPE; INJECTIONS, INTRAMUSCULAR; NOROVIRUS; RABBITS; VACCINATION; VACCINES, SYNTHETIC; VACCINES, VIROSOME; VIRAL VACCINES;

EID: 84860997673     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.03.050     Document Type: Article

References (42)

1. Green K.Y. Caliciviridae: The Noroviruses. Fields virology 2007, 949-979. Lippincott, Williams & Wilkins, Philadelphia, PA. H.P. Knipe, P.M. Howley (Eds.).
2. Patel M.M., Widdowson M.A., Glass R.I., Akazawa K., Vinje J., Parashar U.D. Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerging Infectious Diseases 2008, 14(August (8)):1224-1231.
3. Jiang X., Wang M., Wang K., Estes M.K. Sequence and genomic organization of Norwalk virus. Virology 1993, 195(July (1)):51-61.
4. Jiang X., Wang M., Graham D.Y., Estes M.K. Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. Journal of Virology 1992, 66(November (11)):6527-6532.
5. Parker T.D., Kitamoto N., Tanaka T., Hutson A.M., Estes M.K. Identification of Genogroup I and Genogroup II broadly reactive epitopes on the norovirus capsid. Journal of Virology 2005, 79(June (12)):7402-7409.
6. Herbst-Kralovetz M., Mason H.S., Chen Q. Norwalk virus-like particles as vaccines. Expert Review of Vaccines 2010, 9(March (3)):299-307.
7. Hansman G.S., Natori K., Shirato-Horikoshi H., Ogawa S., Oka T., Katayama K., et al. Genetic and antigenic diversity among noroviruses. Journal of General Virology 2006, 87(April (Pt 4)):909-919.
8. Zheng D.P., Ando T., Fankhauser R.L., Beard R.S., Glass R.I., Monroe S.S. Norovirus classification and proposed strain nomenclature. Virology 2006, 346(March (2)):312-323.
9. Mesquita J.R., Barclay L., Nascimento M.S., Vinje J. Novel norovirus in dogs with diarrhea. Emerging Infectious Diseases 2010, 16(June (6)):980-982.
10. Siebenga J.J., Vennema H., Zheng D.P., Vinje J., Lee B.E., Pang X.L., et al. Norovirus illness is a global problem: emergence and spread of norovirus GII.4 variants, 2001-2007. Journal of Infectious Diseases 2009, 200(September (5)):802-812.
11. Zheng D.P., Widdowson M.A., Glass R.I., Vinje J. Molecular epidemiology of genogroup II-genotype 4 noroviruses in the United States between 1994 and 2006. Journal of Clinical Microbiology 2010, 48(January (1)):168-177.
12. Lindesmith L.C., Donaldson E.F., Lobue A.D., Cannon J.L., Zheng D.P., Vinje J., et al. Mechanisms of GII.4 norovirus persistence in human populations. PLoS Medicine 2008, 5(February (2)):e31.
13. Siebenga J.J., Vennema H., Renckens B., de Bruin E., van der Veer B., Siezen R.J., et al. Epochal evolution of GGII.4 norovirus capsid proteins from 1995 to 2006. Journal of Virology 2007, 81(Sepetember (18)):9932-9941.
14. Bok K., Abente E.J., Realpe-Quintero M., Mitra T., Sosnovtsev S.V., Kapikian A.Z., et al. Evolutionary dynamics of GII.4 noroviruses over a 34-year period. Journal of Virology 2009, 83(November (22)):11890-11901.
15. Ball J.M., Graham D.Y., Opekun A.R., Gilger M.A., Guerrero R.A., Estes M.K. Recombinant Norwalk virus-like particles given orally to volunteers: phase I study. Gastroenterology 1999, 117(July (1)):40-48.
16. Tacket C.O., Sztein M.B., Losonsky G.A., Wasserman S.S., Estes M.K. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clinical Immunology 2003, 108(September (3)):241-247.
17. El-Kamary S.S., Pasetti M.F., Mendelman P.M., Frey S.E., Bernstein D.I., Treanor J.J., et al. Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. Journal of Infectious Diseases 2010, 202(December (11)):1649-1658.
18. Wyatt R.G., Dolin R., Blacklow N.R., DuPont H.L., Buscho R.F., Thornhill T.S., et al. Comparison of three agents of acute infectious nonbacterial gastroenteritis by cross-challenge in volunteers. Journal of Infectious Disease 1974, 129(June (6)):709-714.
19. Bok K., Parra G.I., Mitra T., Abente E., Shaver C.K., Boon D., et al. Chimpanzees as an animal model for human norovirus infection and vaccine development. Proceedings of the National Academy of Sciences of the United States of America 2011, 108(January (1)):325-330.
20. LoBue A.D., Lindesmith L., Yount B., Harrington P.R., Thompson J.M., Johnston R.E., et al. Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains. Vaccine 2006, 24(June (24)):5220-5234.
21. Green K.Y., Kapikian A.Z., Valdesuso J., Sosnovtsev S., Treanor J.J., Lew J.F. Expression and self-assembly of recombinant capsid protein from the antigenically distinct Hawaii human calicivirus. Journal of Clinical Microbiology 1997, 35(July (7)):1909-1914.
22. Leite J.P., Ando T., Noel J.S., Jiang B., Humphrey C.D., Lew J.F., et al. Characterization of Toronto virus capsid protein expressed in baculovirus. Archives of Virology 1996, 141(5):865-875.
23. Green K.Y., Lew J.F., Jiang X., Kapikian A.Z., Estes M.K. Comparison of the reactivities of baculovirus-expressed recombinant Norwalk virus capsid antigen with those of the native Norwalk virus antigen in serologic assays and some epidemiologic observations. Journal of Clinical Microbiology 1993, 31(August (8)):2185-2191.
24. Lew J.F., Kapikian A.Z., Jiang X., Estes M.K., Green K.Y. Molecular characterization and expression of the capsid protein of a Norwalk-like virus recovered from a Desert Shield troop with gastroenteritis. Virology 1994, 200(April (1)):319-325.
25. Harrington P.R., Lindesmith L., Yount B., Moe C.L., Baric R.S. Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice. Journal of Virology 2002, 76(December (23)):12335-12343.
26. Cannon J.L., Lindesmith L.C., Donaldson E.F., Saxe L., Baric R.S., Vinje J. Herd immunity to GII.4 noroviruses is supported by outbreak patient sera. Journal of Virology 2009, 83(June (11)):5363-5374.
27. Chandran A., Santosham M. RotaTeq: a three-dose oral pentavalent reassortant rotavirus vaccine. Expert Review of Vaccines 2008, 7(December (10)):1475-1480.
28. Ehrenfeld E., Modlin J., Chumakov K. Future of polio vaccines. Expert Review of Vaccines 2009, 8(July (7)):899-905.
29. Ellebedy A.H., Webby R.J. Influenza vaccines. Vaccine 2009, 27(November (Suppl. 4)):D65-D68.
30. McBurney S.P., Ross T.M. Viral sequence diversity: challenges for AIDS vaccine designs. Expert Review of Vaccines 2008, 7(November (9)):1405-1417.
31. Duffy S., Shackelton L.A., Holmes E.C. Rates of evolutionary change in viruses: patterns and determinants. Nature Reviews. Genetics 2008, 9(April (4)):267-276.
32. McBurney S.P., Ross T.M. Human immunodeficiency virus-like particles with consensus envelopes elicited broader cell-mediated peripheral and mucosal immune responses than polyvalent and monovalent Env vaccines. Vaccine 2009, 27(July (32)):4337-4349.
33. Gaschen B., Taylor J., Yusim K., Foley B., Gao F., Lang D., et al. Diversity considerations in HIV-1 vaccine selection. Science 2002, 296(June (5577)):2354-2360.
34. Treanor J.J., Jiang X., Madore H.P., Estes M.K. Subclass-specific serum antibody responses to recombinant Norwalk virus capsid antigen (rNV) in adults infected with Norwalk, Snow Mountain, or Hawaii virus. Journal of Clinical Microbiology 1993, 31(June (6)):1630-1634.
35. Giannini S.L., Hanon E., Moris P., Van Mechelen M., Morel S., Dessy F., et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006, 24(August (33-34)):5937-5949.
36. Haynes J.R., Dokken L., Wiley J.A., Cawthon A.G., Bigger J., Harmsen A.G., et al. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. Vaccine 2009, 27(January (4)):530-541.
37. Liao H.X., Sutherland L.L., Xia S.M., Brock M.E., Scearce R.M., Vanleeuwen S., et al. A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 2006, 353(September (2)):268-282.
38. Weaver E.A., Lu Z., Camacho Z.T., Moukdar F., Liao H.X., Ma B.J., et al. Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen. Journal of Virology 2006, 80(July (14)):6745-6756.
39. Kothe D.L., Decker J.M., Li Y., Weng Z., Bibollet-Ruche F., Zammit K.P., et al. Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. Virology 2007, 360(March (10)):218-234.
40. Kothe D.L., Li Y., Decker J.M., Bibollet-Ruche F., Zammit K.P., Salazar M.G., et al. Ancestral and consensus envelope immunogens for HIV-1 subtype C. Virology 2006, 352(September (2)):438-449.
41. Atmar R.L., Bernstein D.I., Harro C.D., Al-Ibrihim M.S., Chen W.H., Ferreira J., et al. Norovirus vaccine against experimental human norwalk virus illness. The New England Journal of Medicine 2011, 365(December (23)):2178-2187.
42. Parra GI, Abente EJ, Sandoval-Jaime C, Sosnovtsev SV, Bok K, Green KY. Multiple antigenic sites are involved in blocking the interaction of GII.4 norovirus capsid with ABH histo-blood group antigens. Journal of Virology 2012, Accepted.